![An Exhilarating Win: ARS Pharmaceuticals Surpasses Earnings Expectations in Q4 of 2023 1 SPRY stock - SPRY Stock Earnings: ARS Pharmaceuticals Beats EPS for Q4 2023](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600-768x432.png)
Source: iQoncept / Shutterstock
ARS Pharmaceuticals (NASDAQ:SPRY) has recently unveiled its triumph for the fourth quarter of 2023.
- Reporting earnings per share of -7 cents, ARS Pharmaceuticals exceeded the forecasted EPS of -14 cents by analysts.
- The quarter did not witness any reported revenue from the company.
Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/03/spry-stock-earnings-ars-pharmaceuticals-for-q4-of-2023/.
©2024 InvestorPlace Media, LLC